Evidence map›Paper›PMID 40195196›Full record

ReviewArchives of dermatological research2025

A novel ITGB2 variant in a patient with severe recurrent pyoderma gangrenosum-like lesions and underlying leukocyte adhesion deficiency type I: case report and literature review.

Leyla Norouzi-Barough, Nasrin Alipour Olyaei, Raphael Carapito, Anne Molitor, Sajjad Biglari, Nazila Poostiyan, Mohammad Shahrooei, Hassan Vahidnezhad, Mohammad Amin Tabatabaiefar, Seiamak Bahram and 1 more

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Leyla Norouzi-BaroughImmunodeficiency Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Nasrin Alipour OlyaeiLaboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Centre de Recherche d'Immunologie et d'Hématologie and Centre de Recherche en Biomédecine de Strasbourg (CRBS), Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Fédération Hospitalo-Universitaire OMICARE, Université de Strasbourg, Strasbourg, France.
Raphael CarapitoLaboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Centre de Recherche d'Immunologie et d'Hématologie and Centre de Recherche en Biomédecine de Strasbourg (CRBS), Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Fédération Hospitalo-Universitaire OMICARE, Université de Strasbourg, Strasbourg, France.
Anne MolitorLaboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Centre de Recherche d'Immunologie et d'Hématologie and Centre de Recherche en Biomédecine de Strasbourg (CRBS), Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Fédération Hospitalo-Universitaire OMICARE, Université de Strasbourg, Strasbourg, France.
Sajjad BiglariDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Nazila PoostiyanSkin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammad ShahrooeiClinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium.
Hassan VahidnezhadDivision of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Mohammad Amin TabatabaiefarDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Seiamak BahramLaboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, Centre de Recherche d'Immunologie et d'Hématologie and Centre de Recherche en Biomédecine de Strasbourg (CRBS), Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Fédération Hospitalo-Universitaire OMICARE, Université de Strasbourg, Strasbourg, France. siamak@unistra.fr.
Roya SherkatImmunodeficiency Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Royasherkat@yahoo.com.

Funding

IdEx Unistra and SFRI ANR-10-IDEX-0002/ANR-20-SFRI-0012Immunodeficiency Diseases Research Center 2402308Vice Chancellor for Research of Isfahan University of Medical Sciences 3401343
6 · The paper itself

Abstract

Leukocyte adhesion deficiency (LAD) is a group of inborn errors of immunity caused by mutations of integrin subunit b2 gene (ITGB2). Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis characterized by recurrent, sterile, and enlarging necrotic ulcers which may manifest as a single or multiple new lesions simultaneously. Here we report a 43-year-old woman from a consanguine marriage who was diagnosed with LAD-I in childhood, recurrent severe PG-like lesion, and atypical manifestations including celiac disease and low CD19 B-cell subsets. A targeted genetic panel revealed a novel homozygous missense variant c.988T>C (Tyr330His) in ITGB2 gene. While the treatment with prednisolone, cyclosporine, and antibiotics led to partial improvement, the patient unfortunately discontinued the therapy and later died from septicemia. Early hematopoietic cell transplantation (HCT) shortly after birth can be highly effective in managing patients with LAD and preventing life-threatening infections. However, evidence suggests that HCT does not prevent autoinflammatory and autoimmune disorders such as PG. Therefore, it is important to monitor LAD patients for the potential development of PG, even after HCT.

Indexed as

CD18 AntigensLeukocyte-Adhesion Deficiency SyndromePyoderma GangrenosumAdultConsanguinityFatal OutcomeFemaleHematopoietic Stem Cell TransplantationHumansMutation, MissenseRecurrenceSkinCD18 AntigensITGB2LAD-IPyoderma gangrenosum

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.